Drug
Ampreloxetine
Ampreloxetine: highest development phase Phase 3, developed by Theravance Biopharma. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Theravance Biopharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ampreloxetine NCT05696717 | Phase 3 | Symptomatic Neurogenic Orthostatic Hypotension |
| ampreloxetine NCT03829657 | Phase 3 | Symptomatic Neurogenic Orthostatic Hypotension |
| ampreloxetine NCT04095793 | Phase 3 | Symptomatic Neurogenic Orthostatic Hypotension |
| ampreloxetine NCT03750552 | Phase 3 | Symptomatic Neurogenic Orthostatic Hypotension |
| Ampreloxetine NCT04200573 | Phase 1 | Symptomatic Neurogenic Orthostatic Hypertension |
Latest
No recent events.
Follow Ampreloxetine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.